Breast Cancer Screening Market, Size, Global Forecast 2022-2027, Industry Trends, Growth, Outlook, Impact of COVID-19, Company Analysis

Breast Cancer Screening Market, Size, Global Forecast 2022-2027, Industry Trends, Growth, Outlook, Impact of COVID-19, Company Analysis

  • April 2022 •
  • 410 pages •
  • Report ID: 6272174 •
  • Format: PDF
Breast Cancer Screening Market, Size, Global Forecast 2022-2027, Industry Trends, Growth, Outlook, Impact of COVID-19, Company Analysis

Global Breast Cancer Screening Market will surpass US$ 52.82 Billion by 2027. Worldwide, breast cancer is one of the most common types of cancer and a significant cause of mortality among women. Thus, early detection is required for breast cancer diseases. Breast cancer is more general in industrialized countries due to its modern lifestyle; the incidence rate increases in developing countries. In 2020, as per (World Health Organization) WHO, there were 2.3 million women diagnosed with breast cancer and 685000 deaths due to breast cancer globally.

Consequently, regular screening is essential to prevent malignancy. Breast cancer screening is a routine examination to detect breast cancer. Early detection could provide timely treatment of patients, thereby reducing the mortality rate. Breast cancer screening generally involves an MRI scan, mammography, or ultrasound.

Worldwide Breast Cancer Screening Market Size has reached US$ 41.75 Billion in 2021

Global drivers of the breast screening market include strengthened awareness of the benefits of breast cancer screening programs and the demand to enhance the accuracy of breast cancer detection. This, alongside a patient-centric method of screening and technological advancements to improve patient convenience, is being implemented to boost participation in screening programs, which has moved mammography X-ray screening equipment uptake.

COVID-19 Impact on Global Breast Cancer Screening Industry:

COVID-19 has severely affected all medical procedures and healthcare facilities since the pandemic was declared globally in 2020. The breast screening industry was significantly affected, with many females missing scheduled mammograms. With such a growing population of women missing breast cancer screening appointments, there is a significant problem that many more women will develop later stages of breast cancer in the coming year. Nevertheless, to help deal with the patient backlog, a considerable investment will be needed in medical staff and breast screening equipment. While the raised pressure on screening centers and hospitals to address the number of women requiring breast cancer screening.

Mammography Is Expected to Dominate in The Global Breast Cancer Screening Test Segment:

The most typically used screening test for breast cancer is the imaging test, and these imaging tests are regarded as the most reliable ones. Mammography is the most widely utilized test to screen for breast cancer. Since mammography is the standard gold method used to screen for breast cancer, governments, and other healthcare associations worldwide are taking initiatives to provide women aged 50 to 75 access to mammography screening. This boosts the global demand for mammography while laboratory and blood tests and other imaging tests are acquiring popularity.

Further, digital breast tom synthesis can expand the diagnostic accuracy of mammography and is employed to assess suspicious or equivocal, or mammography findings. Other screening tests like ultrasound and contrast-enhanced magnetic resonance imaging (MRI) play a vital role in breast cancer diagnostics, staging, and follow-up. According to the research, Global Breast Cancer Screening Industry will expand at a CAGR of 4.00% during 2021-2027.

Region-Wise Segmentation of Global Breast Cancer Screening Market:

Region-Wise, Global Breast Screening Market includes Norway, Switzerland, China, United Kingdom, Germany, Italy, Spain, Netherlands, India, Korea, Japan, Singapore, Thailand, Malaysia, Brazil, Australia, New Zealand, United States, Canada, France, South Africa, United Arab Emirates, Saudi Arabia. North America currently dominates the breast cancer screening test market and is expected to continue its stronghold for a few more years. The United States holds a significant market in the North American region. This can be attributed to the rising incidence rates of breast cancer and increasing awareness among the population for the early detection of breast cancer. The presence of the expanded healthcare infrastructure is anticipated to propel the breast cancer screening market in the United States.

Key Companies:

Global breast cancer screening major market players are AstraZeneca, Novartis, Sanofi, Pfizer, and Bayer AG. The market players contribute considerably to market maturation by embracing various strategies, including mergers and acquisitions, collaborations with the government, new product launches and technological advancements to remain competitive.

Renub Research latest study report “Breast Cancer Screening Market, Population, By Screening Tests [Mammography, Magnetic Resonance Imaging (MRI) & Ultrasound] Countries (United States, Canada, France, United Kingdom, Germany, Italy, Spain, Netherlands, Norway, Switzerland, China, India, Korea, Japan, Singapore, Thailand, Malaysia, Brazil, Australia, New Zealand, South Africa, United Arab Emirates, Saudi Arabia), Company Analysis (AstraZeneca, Novartis, Sanofi, Pfizer, Bayer AG)” provides a detailed and comprehensive insight of the Breast Cancer Diagnostics Industry.

Screening Tests, - The Market has been Covered from 3 viewpoints
1. Mammography
2. Magnetic Resonance Imaging (MRI)
3. Ultrasound

Countries - The Market has been covered for 23 Countries:
1. United States
2. Canada
3. United Kingdom
4. France
5. Germany
6. Italy
7. Spain
8. Netherlands
9. Norway
10. Switzerland
11. India
12. China
13. Japan
14. Korea
15. Singapore
16. Thailand
17. Malaysia
18. Brazil
19. Australia
20. New Zealand
21. South Africa
22. United Arab Emirates
23. Saudi Arabia

All the companies have been studied from two points
• Recent Developments
• Sales Analysis

Company Analysis
1. AstraZeneca
2. Novartis
3. Sanofi
4. Pfizer
5. Bayer AG